A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels "TNT"


Phase 4 Results

Summary of Purpose

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 1 May 2007.

1 Apr 1998 16 May 2006 Unavailable 1 Aug 2004 1 May 2007 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double-Blind
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Pfizer CT.gov Call Center Pfizer